

Anosmia in COVID-19 patients

Daniel Hornuss, M.D.¹, Berit Lange, M.D.², Nils Schröter³, M.D., Siegbert Rieg, M.D.¹, Winfried V. Kern, M.D.¹, Dirk Wagner, M.D.^{1*}

¹ Section of Infectious Diseases, Department of Internal Medicine II, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany

² Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany

³ Department of Neurology and Neurophysiology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany

* Corresponding author: Dirk Wagner, Section of Infectious Diseases, Department of Internal Medicine II, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany. Tel. ++49-761-270 18190, Fax ++49-761 270 18200, email: dirk.wagner@uniklinik-freiburg.de

Manuscript Word Count: 1041 (of 1200) – Research Note

Abstract Word Count 206 (of 250)

Reference Number: 10

Number of Tables: 1

Number of Figures: 1

Key words: SARS-CoV-2, COVID-19, Anosmia, Hyposmia, Smelling dysfunction, Sniffin-test

Anosmia in COVID-19 patients – Manuscript – DW

27 **Abstract:**

28

29 **Objectives:** Coronaviruses (CoVs) have a neuroinvasive propensity, and the frequently reported
30 symptoms of smelling and taste dysfunction in many COVID-19 patients may be related to the
31 respective capability of SARS-CoV2, the cause of the current pandemic. In this study we objecti-
32 fied and quantified the magnitude and underreporting of the smelling dysfunction caused by
33 COVID-19 using a standardized test.

34 **Methods:** We conducted a prospective cross-sectional study comparing the proportion of anos-
35 mia using Sniffin-sticks in those reporting a loss of smell, in those who did not as well as in unin-
36 fected controls. The outcome of anosmic versus not anosmic patients were recorded during
37 hospital stay and at day 15 on a six-category ordinal scale. The study was approved by the insti-
38 tutional review board, all participants consented to the study.

39 **Results:** 40% of 45 consecutive hospitalized COVID-19 patients and 0% of 45 uninfected con-
40 trols consenting were diagnosed with anosmia. 44% of anosmic and 50% of hyposmic patients
41 did not report having smelling problems. Anosmia or hyposmia was not predictive of a severe
42 COVID-19 manifestation.

43 **Conclusions:** The majority of COVID-19 patients have an objective anosmia and hyposmia,
44 which often occurs unnoticed. These symptoms may be related to the neuroinvasive propensity
45 of SARS-COV-2 and the unusual presentation of COVID-19 disease manifestations.

46

Anosmia in COVID-19 patients – Manuscript – DW

47 **Introduction:** Coronaviruses (CoVs) including SARS-CoV-2, the cause of the current pandemic
48 of coronavirus disease 2019 (COVID-19), have a neuroinvasive propensity[1,2], with the olfacto-
49 rial neurons being currently discussed as portal of entry for neuroinvasion [3] and a spread of
50 CoVs after infection of neural cells from CNS to the periphery via a transneural route [1]. A rele-
51 vant proportion of admitted COVID-19 patients report the disturbances of taste or smelling [4],
52 without any other obvious cause like nasal obstruction or rhinorrhea, which may be related to
53 this capability. In this study we objectified the magnitude of the smelling disorder caused by
54 SARS-CoV-2.

55

56 **Methods:** Burghart-Sniffin'-Sticks®, a widely used screening test for smelling disorders, was
57 used; according to the manufacturers specifications anosmia, hyposmia and normosmia, were
58 defined as correctly identifying 1-6, 7-10, and 11-12 odors, respectively [5,6]. We conducted a
59 prospective cross-sectional study at the Medical Center - University of Freiburg, Germany in
60 April 2020 comparing the proportion of anosmia in patients with positive PCR result for SARS-
61 CoV-2 in nasopharyngeal swaps or sputum using Sniffin-sticks in those reporting a loss of smell,
62 in those who did not as well as in uninfected patients and health care workers as controls. Pa-
63 tients younger than 18 years, with known smelling disorder or who did not consent to the study
64 were excluded. Assuming a prevalence of anosmia of 5% in the uninfected control group [6], the
65 sample size was calculated to test the null hypothesis that anosmia in COVID-19 is the same as
66 in controls and to find a significant difference using the chi square test with a power of >90%. To
67 compare clinical course (symptoms, laboratory values at the time of the Sniffin test) and out-
68 come of anosmic versus not anosmic patients the worst outcomes during the hospital stay and
69 at day 15 on a six-category ordinal scale (1. discharged; 2. hospitalized, not requiring supple-
70 mental oxygen; 3. hospitalized, requiring supplemental oxygen; 4. hospitalized, on (NIV) or high
71 flow oxygen devices; 5. hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal
72 membrane oxygenation (ECMO); 6. death) were recorded.

Anosmia in COVID-19 patients – Manuscript – DW

73 The study was approved by the University hospital ethical committee (No. 184/20), written in-
74 formed consent was obtained from all participants in the study. Study protocol and data set are
75 available from the corresponding author upon request.

76

77 **Results:** We tested 45 consecutive hospitalized COVID-19 patients and 45 uninfected controls
78 (age (median years \pm STD) 56 ± 16.9 and 54 ± 18.3 , respectively) consenting to the study (ta-
79 ble). The controls correctly identified a median of 11 out of 12 odors of Sniffin' Sticks, none was
80 anosmic, 12/45 (27%, 95%CI 14-41%, age (median years \pm STD) 63 ± 19.6) were hyposmic,
81 and 33 (73%, 95%CI 58-85%, age (median years \pm STD) 49 ± 10.2) were normosmic. A higher
82 percentage (18/45, 40%) of COVID-19 patients were diagnosed with anosmia ($p < 0,001$; table).
83 COVID-19 patients smell on average 4 sticks less than uninfected controls (figure). The Sniffin'
84 Stick test was more sensitive in detecting anosmia in comparison to self-reporting or taking a
85 medical history: 44% of anosmic and 50% of hyposmic patients did not report having smelling
86 problems. The clinical picture, laboratory test results, and outcome at day 15 or by counting the
87 worst outcome during the hospital stay defined by a rating on a 6-point ordinal scale was similar
88 in patients with and without anosmia or hyposmia (table).

89

90 **Discussion:** Hyposmia and anosmia are symptoms often noticed by COVID-19 patients [4].
91 Using a quantitative and objective test almost half of the patients were anosmic, and another 40
92 % hyposmic. Still in our cohort only 49% of patients reported a smelling dysfunction, which is
93 more than in a recently published survey [4], but significantly less in comparison to what was
94 diagnosed by the Sniffin' test . E.g. the magnitude of the olfactory dysfunction in COVID-patients
95 is underreported with more than 80% of COVID-19 patients having hyposmia or anosmia, in
96 comparison to the uninfected controls, where no participant was anosmic and 27% hyposmic. In
97 a large German community sample ($n = 7267$) a similar low percentage of anosmia (5%) has
98 been reported using the same test; however the 12-stick-test is not able to distinguish properly
99 between hyposmia and normosmia [6], thus the high percentage of 44 % of our COVID-19 pa-
100 tients with hyposmia needs to be interpreted carefully. Patients were not tested after having

Anosmia in COVID-19 patients – Manuscript – DW

101 been discharged, but telephone interviews even with patients with mild to moderate COVID-19
102 showed that not all patients had returned to normal smelling 15 days after start of first symptoms
103 although no other symptoms persisted.

104

105 Olfactorial neurons are discussed as portal of entry for neuroinvasion of CoVs which may be
106 transferred to the Central Nervous System (CNS) via a synapse-connected route [2]. It is unclear
107 whether olfactory sensory neurons are directly involved in the pathogenesis of smelling loss in
108 COVID-19, since they have not been shown to coexpress Transmembrane protease, serine 2
109 (TMPRSS2) and Angiotensin Converting Enzyme 2 (ACE2), which are central for entry of SARS-
110 CoV-2 into human cells [7]. In fact, the detection of the expression of these proteins in coexpres-
111 sion in olfactory sustentacular cells [7] does not preclude the direct involvement of olfactory sen-
112 sory neurons in COVID-19 associated smelling loss. In a mouse model infected with another
113 human coronavirus, e.g. HCoV-OC43, viral antigen is detected only in the olfactory bulb after 3
114 and in the whole brain tissue after 7 days [8]. Given the wide distribution of the Angiotensin Con-
115 verting Enzyme 2 (ACE2)-receptor in the brain [9], the observation that HCoV are able to induce
116 direct neuronal injury within brainstem cardiorespiratory centers in experimental animal models
117 [2] and the increasing evidence that SARS-CoV 2 is also causing neurological complications, the
118 clinical presentation of COVID-19 patients with deterioration at around one week and the acute
119 respiratory failure may be related to the neuroinvasive potential of SARS-CoV-2 [10].

120

121 In conclusion all COVID-19 patients should be interviewed and – if possible tested - for olfactory
122 disorders that occur often in COVID-19. Some patients have presented solely with this symptom,
123 e.g. primary physicians and otolaryngologist need to be aware of this putative presentation. Our
124 study shows that anosmia and hyposmia often occurs unnoticed in COVID-19 patients, and that
125 for those patients an objective and quantifiable test is required. Anosmia is not a predictor of a
126 severe COVID-19 manifestation.

127

Anosmia in COVID-19 patients – Manuscript – DW

128 **Funding:** This work was supported by the Berta-Ottenstein-Programme for Clinician Scientists,
129 Faculty of Medicine, University of Freiburg, to NS.

130

131 **Acknowledgements:** We sincerely thank Kamilla Szabo, M.D. and Annegrit Decker, M.D. (De-
132 partment of Internal Medicine II, Medical Center – University of Freiburg, Germany) for taking
133 care of the patients during the study allowing DH to test the participants.

134

135 **Reproducible Research Statement:** Study protocol and data set: Available from Prof. Dr. D.
136 Wagner (e-mail, dirk.wagner@uniklinik-freiburg.de).

137

138 **Disclosure:** The authors report no disclosures relevant to the manuscript

139

Anosmia in COVID-19 patients – Manuscript – DW

140 **Legend to Figures:**

141 **Figure: Number of correctly identified odors.** The Sniffin test uses 12 different odors; the
142 percentage of participants (y-axes; COVID-19 patients black bars; controls white bars) correctly
143 identifying the respective number (n, x-axes) of odors is shown. The dashed lines define the cut-
144 off between anosmia, hyposmia, and normosmia according to the test guidelines [5].

145

146 **References**

- 147 [1] Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory
148 Virus Infections. *Front Cell Neurosci* 2018;12:386.
149 <https://doi.org/10.3389/fncel.2018.00386>.
- 150 [2] Li Y-C, Bai W-Z, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role
151 in the respiratory failure of COVID-19 patients. *J Med Virol* 2020.
152 <https://doi.org/10.1002/jmv.25728>.
- 153 [3] Swanson PA, McGavern DB. Viral diseases of the central nervous system. *Curr Opin Virol*
154 2015;11:44–54. <https://doi.org/10.1016/j.coviro.2014.12.009>.
- 155 [4] Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfac-
156 tory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. *Clin Infect Dis*
157 2020. <https://doi.org/10.1093/cid/ciaa330>.
- 158 [5] Hummel T, Rosenheim K, Konnerth C-G, Kobal G. Screening of Olfactory Function with a
159 Four-Minute Odor Identification Test: Reliability, Normative Data, and Investigations in Pa-
160 tients with Olfactory Loss. *Ann Otol Rhinol Laryngol* 2001;110:976–81.
161 <https://doi.org/10.1177/000348940111001015>.
- 162 [6] Hinz A, Luck T, Riedel-Heller SG, Herzberg PY, Rolffs C, Wirkner K, et al. Olfactory dys-
163 function: properties of the Sniffin' Sticks Screening 12 test and associations with quality of
164 life. *Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger*
165 *Soc Oto-Rhino-Laryngol - Head Neck Surg* 2019;276:389–95.
166 <https://doi.org/10.1007/s00405-018-5210-2>.
- 167 [7] Fodoulian L, Tuberosa J, Rossier D, Landis B, Carleton A, Rodriguez I. SARS-CoV-2 re-
168 ceptor and entry genes are expressed by sustentacular cells in the human olfactory neu-
169 roepithelium. *Neuroscience*; 2020. <https://doi.org/10.1101/2020.03.31.013268>.
- 170 [8] St-Jean JR, Jacomy H, Desforges M, Vabret A, Freymuth F, Talbot PJ. Human respiratory
171 coronavirus OC43: genetic stability and neuroinvasion. *J Virol* 2004;78:8824–34.
172 <https://doi.org/10.1128/JVI.78.16.8824-8834.2004>.
- 173 [9] Kabbani N, Olds JL. Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher
174 Risk. *Mol Pharmacol* 2020;97:351–3. <https://doi.org/10.1124/molpharm.120.000014>.
- 175 [10] Pérez CA. Looking ahead: The risk of neurologic complications due to COVID-19. *Neurol*
176 *Clin Pract* 2020;10.1212/CPJ.0000000000000836.
177 <https://doi.org/10.1212/CPJ.0000000000000836>.
- 178

Table: Characteristics and results of COVID-19 patients.

		all	with anosmia *	with hyposmia	with normosmia
All (n, %, 95 CI)		45	18 (40%; 25-55%)	20 (44%, 29-60%)	7 (15%, 5-25%)
Sex (n)	female	20	8	8	4
	male	25	10	12	3
Age (median ± STD)	Years	56 ± 16.9	56.5 ± 17.9	58 ± 17.5	49 ± 10.2
Symptoms (n, %)	Temp ≥ 38,5°C	35 (78%)	12 (34%)	16 (46%)	7 (20%)
	Cough	28 (62%)	14 (50%)	10 (36%)	4 (14%)
	Headache	10 (22%)	6 (60%)	4 (40%)	0
	Shortness of Breath	20 (44%)	13 (65%)	5 (25%)	2 (10%)
Laboratory values (mean ± STD) §	Leukocytes (Ths/μl)	5.6 ± 2.8	6.3 ± 3.3	5.5 ± 1.9	4.3 ± 3.8
	Lymphocytes (Ths/μl)	1.1 ± 0.7	0.8 ± 0.6	1.1 ± 0.8	1.4 ± 0.8
	CRP (mg/l)	49 ± 50	60 ± 42	46 ± 49	19 ± 75
	PCT (ng/ml)	0.12 ± 1.3	0.13 ± 0.1	0.17 ± 2.0	0.1 ± 0.1
	IL6 (pg/ml)	26 ± 44	16 ± 34	27 ± 51	47 ± 44
	LDH (U/l)	284 ± 181	294 ± 258	271 ± 148	249 ± 75
Sniffin Test (median)	correctly identified odors #	8	3	9	11
Report of impaired smelling (n, %, 95CI) ¶	yes	22 (49%)	10 (45%, 24-68%)	10 (45%, 24-68%)	2 (10%, 1-29%)
	no	23 (51%)	8 (34%, 16-57%)	10 (43%, 23-65%)	5 (21%, 7-43%)
Time course (days; median ± STD)	first symptom to first positive PCR result	2 ± 4.2	2 ± 4.1	1.5 ± 3.7	2 ± 4
	first symptom to reported impaired smelling	5 ± 3.04	6.5 ± 3	2.5 ± 2.7	5.5 ± 2.5
	first symptoms to Sniffin test	10 ± 5.1	11 ± 4	8.5 ± 4.5	12 ± 7.5
	first positive PCR result to Sniffin test	4 ± 4.6	3.5 ± 3.9	4 ± 4.4	5 ± 6.3
Clinical course during hospital stay (n, %) ‡	Discharged	23 (51%)	11 (48%)	9 (39%)	3 (13%)
	No oxygen	27 (68%)	8 (30%)	13 (48%)	6 (22%)
	Supplemental oxygen	15 (33%)	7 (47%)	7 (47%)	1 (7%)
	NIV or high flow oxygen	2 (4%)	2 (100%)	0	0
	IMV or ECMO	0	0	0	0
	Death	1 (2%)	1 (100%)	0	0
Outcome at day 15 (n, %) †	Discharged	17 (41%)	7 (41%)	6 (35%)	4 (24%)
	No oxygen	14 (32%)	3 (21%)	8 (57%)	3 (21%)
	Supplemental oxygen	9 (22%)	7 (78%)	2 (22%)	0
	NIV or high flow oxygen	0	0	0	0
	IMV or ECMO	0	0	0	0
	Death	1 (2%)	1 (100%)	0	0

COVID-19 patients diagnosed with Sniffin' sticks as normosmic, hyposmic or anosmic (e.g. correctly identifying 11-12, 7-10, and 0-6 odors of Sniffin' sticks, respectively) are shown. n, number; %, percentage; STD, standard deviation; 95%CI, 95% confidence interval; PCR, polymerase chain reaction; NIV = non-invasive ventilation; IMV, invasive mechanical ventilation; ECMO, extracorporeal membrane oxygenation. § ± 2 days from the day of testing, n=33-41. # Linear regression analysis adjusted for age and sex show that COVID-19 patients on average smell 4 sticks less than uninfected controls. ¶ at the day of testing. ‡ the worst outcome was recorded. † n = 41. *p< 0,001, chi square test with null hypothesis that anosmia in COVID-19 is the same as in controls.

